[{"Assets_0_Q3_USD":2333800000.0,"CommonStockSharesOutstanding_0_Q3_shares":51600000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":65900000.0,"NetIncomeLoss_1_Q3_USD":43200000.0,"NetIncomeLoss_3_Q3_USD":7600000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":51600000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":51400000.0,"StockholdersEquity_0_Q3_USD":1035000000.0,"EarningsPerShareBasic_1_Q3_USD":0.84,"EarningsPerShareBasic_3_Q3_USD":0.15,"Ticker":"EBS","CIK":"1367644","name":"EMERGENT BIOSOLUTIONS INC.","OfficialName":"Emergent Biosolutions Inc. Common Stock","form":"10-Q","period":"20190930","fy":"2019.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"2077670312.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NYSE","SP500":"nan","filed":"20191107"}]